SBIR/STTR Research Award

Novel method to create knockout rats using endonucleases and spermatogonial stem

Award identifier 2bc5a9113e649e7f6889d17c15de1e90284a1737bb34f38fe8d2c16d5c8d853dAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$774,736

Program and phase

SBIR · Phase II

Award year

2014

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
Proposal award date
2014-09-15
Contract end date
2017-08-31
UEI
Not reported
Solicitation number
PA13-234
Topic code
200

Research abstract

DESCRIPTION provided by applicant The laboratory rat is a preferred rodent model in pre clinical drug studies Their larger size facilitates procedures otherwise difficult in mice includng studies using instrumentation blood sampling and surgeries and allows for ten times the amount of tissue collection Although rats are often more suitable than mice for pharmacological toxicological physiological and many other biological assays the ease of genetic engineering technologies has made the mouse the preeminent rodent model However the recent emergence of new and more precise gene targeting techniques for the rat has resulted in significant growth in the production of genetically modified rats In Phase I we demonstrated the feasibility of combining custom site specific Xanthomonas TAL Nuclease XTNTM a k a TALEN technology with spermatogonial stem cells SSCs for rapid cost effective and precise genome engineering in the rat Indeed the Phase I studies enabled Transposagen to launch custom XTNTM and knockout rat production services in and we have successfully created and delivered custom knockout rats to both industry and academic investigators In work outside the Phase I project we paired XTN TALEN technology with piggyBacTM technology to create the Footprint FreeTM Gene Editing System the only commercially available system that can engineer as little as a single nucleotide without leaving unwanted mutations and allowing for selection of rare events For Phase II studies we propose to use SSC and Footprint FreeTM Gene Editing technology to create a suite of rats that would express a specific human CP D allele in the absence of the homologous rat Cyp d genes i e humanized CYP D rat models Humans carry a single but highly polymorphic p CYP D gene CYP D metabolizes nearly of current drugs and is represented by over variants in the population which possess a wide range of enzyme activities As a consequence adverse drug effects or lack of drug effect depend on the specific allele s an individual is carrying Humanized CYP D animal models would be of great value for drug testing To accomplish this task we will optimize strategies to simultaneously delete a kb segment of the rat genome that contains the gene Cyp d cluster and knock in a specific human CYP D allele so that it would be placed under transcriptional control of the rat Cyp d promoter to ensure a physiological pattern of expression Not only would the humanized rat be useful for assessing the consequences of CYP D specific metabolites in the whole animal but hepatocytes isolated from these animals would provide a reliable and consistent source of CYP D hepatocytes for in vitro drug metabolism testing More generally successful optimization of Footprint FreeTM Gene Editing protocols for the creation of large scale humanizing knock in mutations would enable for the first time the possibility of sophisticated and cost effective genome engineering in many mammalian organisms PUBLIC HEALTH RELEVANCE The laboratory rat has been a valuable animal model for biomedical research due to its similarity to human physiology Pharmaceutical companies currently rely primarily on animal or transformed cell models for pre clinical metabolism and toxicity testing during drug discovery Thus there is a compelling need for animal models that are more predictive for ADME properties in humans However the ease and lower costs associated with generating mutations in mice has lead to a greater reliance on genetically engineered mouse models despite the inability of many of these models to mimic human pathways We outline a strategy that integrates our expertise in spermatogonial stem cells SSCs with a site specific enzyme technology to create knockout and humanized rat models for drug discovery applications Thus this project would benefit many goals of public health by making the production of mutations in the rat that better model human physiology readily accessible to the research community

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.